RxDoctor Payments Data

David Brooker, MD

Nephrology · Clarion, PANPI 1649214552

Payments from drug & device makers

$20,655in general payments, 2019–2025

Across 347 payments — averaging $59.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$6K
  • AstraZeneca$4K
  • Otsuka America Pharmaceutical, Inc.$3K
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$2K
  • Amgen$1K
  • Travere Therapeutics, Inc.$781
  • plus $3K from 18 others

What the payments were for

  • Speaking & faculty fees$13,42365%
  • Food & beverage$6,82233%
  • Education$4092%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,655 in reported general payments places this provider in the 85th percentile of 586 nephrology providers in Pennsylvania.

See all nephrology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$182,306
Medicare patients
366
Services billed
1,521

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JynarqueTolvaptan31$626,559
FarxigaDapagliflozin Propanediol229$197,500
Tolvaptan15$147,429
RayaldeeCalcifediol62$85,621
KerendiaFinerenone71$79,722
VeltassaPatiromer Calcium Sorbitex31$33,503
AuryxiaFerric Citrate17$18,948
LokelmaSodium Zirconium Cyclosilicate21$18,366
JardianceEmpagliflozin14$15,245
Demeclocycline Hcl22$9,030
Paricalcitol80$8,408
Cinacalcet Hcl19$6,973
Valsartan170$6,198
Sevelamer Carbonate18$2,431
Cyclosporine ModifiedCyclosporine, Modified27$2,416

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Jynarque$3,028$626,55931 claims
AstraZenecaFarxiga, Lokelma$4,482$215,865250 claims
Otsuka Pharmaceutical Development & Commercialization, Inc.Tolvaptan$1,928$147,42915 claims
OPKO Pharmaceuticals, LLCRayaldee$750$85,62162 claims
BayerKerendia$6,408$79,72271 claims
Akebia Therapeutics IncAuryxia$324$18,94817 claims
Boehringer IngelheimJardiance$113$15,24514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 586 nephrology providers in Pennsylvania.

Other nephrology in Clarion

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →